{"id":1874,"date":"2021-08-09T21:37:21","date_gmt":"2021-08-09T18:37:21","guid":{"rendered":"https:\/\/larifan.eu\/eraf\/"},"modified":"2026-10-02T13:33:50","modified_gmt":"2026-10-02T10:33:50","slug":"eraf","status":"publish","type":"page","link":"https:\/\/larifan.eu\/ru\/eraf\/","title":{"rendered":"ERAF"},"content":{"rendered":"

[vc_row overflow=”default” css=”.vc_custom_1643308766592{border-top-width: 60px !important;padding-bottom: 60px !important;}”][vc_column][vc_column_text]<\/p>\n

Jaunas inovat\u012bvas du\u0101la lietojuma medic\u012bnas ier\u012bces izstr\u0101de<\/b><\/span><\/span><\/span><\/span><\/p>\n

SIA\u00a0<\/span><\/span><\/span><\/span>\u201cLarif\u0101ns\u201d<\/b><\/span><\/span><\/span><\/span>\u00a0piedal\u0101s Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonda (ERAF) atbalst\u012bt\u0101 projekt\u0101\u00a0<\/span><\/span><\/span><\/span>\u201cJaunas inovat\u012bvas du\u0101la lietojuma medic\u012bnas ier\u012bces izstr\u0101de\u201d<\/b><\/span><\/span><\/span><\/span>, projekta Nr.\u00a0<\/span><\/span><\/span><\/span>1.2.1.1\/3\/26\/A\/095<\/b><\/span><\/span><\/span><\/span>.<\/span><\/span><\/span><\/span><\/p>\n

Projekta \u012bsteno\u0161ana pl\u0101nota laika period\u0101 no\u00a0<\/span><\/span><\/span><\/span>2026. gada septembra l\u012bdz 2028. gada augustam<\/b><\/span><\/span><\/span><\/span>.<\/span><\/span><\/span><\/span><\/p>\n

Projekta kop\u0113jais bud\u017eets:<\/b><\/span><\/span><\/span><\/span>\u00a01 128 255,00 EUR<\/span><\/span><\/span><\/span><\/p>\n

ES finans\u0113jums:<\/b><\/span><\/span><\/span><\/span>\u00a0857 135,70 EUR<\/span><\/span><\/span><\/span><\/p>\n

Projekta ietvaros paredz\u0113ts izstr\u0101d\u0101t\u00a0<\/span><\/span><\/span><\/span>inovat\u012bvu du\u0101la lietojuma medic\u012bnas ier\u012bci \u2013 pl\u0101ksteri br\u016b\u010du un apdegumu apr\u016bpei<\/b><\/span><\/span><\/span><\/span>, kas apvienos medic\u012bnisk\u0101s apr\u016bpes funkcionalit\u0101ti ar \u012bpa\u0161\u0101m aizsardz\u012bbas un mask\u0113\u0161an\u0101s \u012bpa\u0161\u012bb\u0101m.<\/span><\/span><\/span><\/span><\/p>\n

Izstr\u0101d\u0101jamajam pl\u0101ksterim paredz\u0113ts\u00a0<\/span><\/span><\/span><\/span>\u012bpa\u0161s sl\u0101nis<\/b><\/span><\/span><\/span><\/span>, kas nodro\u0161in\u0101s nepiecie\u0161am\u0101s \u012bpa\u0161\u012bbas br\u016b\u010du un apdegumu apr\u016bpei. Savuk\u0101rt pl\u0101kstera \u0101r\u0113jais\u00a0<\/span><\/span><\/span><\/span>kamufl\u0101\u017eas sl\u0101nis<\/b><\/span><\/span><\/span><\/span>\u00a0paredz\u0113ts, lai samazin\u0101tu t\u0101 infrasarkano un optisko signat\u016bru.<\/span><\/span><\/span><\/span><\/p>\n

\u0160\u0101da pieeja \u013caus izveidot medic\u012bnisku risin\u0101jumu ar\u00a0<\/span><\/span><\/span><\/span>du\u0101lu pielietojumu \u2013 gan civilaj\u0101, gan milit\u0101raj\u0101 jom\u0101<\/b><\/span><\/span><\/span><\/span>. Civilaj\u0101 vid\u0113 izstr\u0101d\u0101tais risin\u0101jums var b\u016bt izmantojams br\u016b\u010du un apdegumu apr\u016bp\u0113, savuk\u0101rt milit\u0101raj\u0101 jom\u0101 \u012bpa\u0161i noz\u012bm\u012bga var b\u016bt pl\u0101kstera sp\u0113ja samazin\u0101t optisko un infrasarkano paman\u0101m\u012bbu.<\/span><\/span><\/span><\/span><\/p>\n

Projekta \u012bsteno\u0161an\u0101\u00a0<\/span><\/span><\/span><\/span>SIA \u201cLarif\u0101ns\u201d<\/b><\/span><\/span><\/span><\/span>\u00a0sniedz savu kompetenci farm\u0101cijas un biotehnolo\u0123iju jom\u0101, piedaloties jauna, uz zin\u0101tnisk\u0101m un tehnolo\u0123isk\u0101m inov\u0101cij\u0101m balst\u012bta medic\u012bnas risin\u0101juma izstr\u0101d\u0113.<\/span><\/span><\/span><\/span><\/p>\n

Projekta rezult\u0101t\u0101 paredz\u0113ts izstr\u0101d\u0101t un p\u0101rbaud\u012bt jaunu medic\u012bnisk\u0101s ier\u012bces risin\u0101jumu, kas apvieno\u00a0<\/span><\/span><\/span><\/span>br\u016b\u010du un apdegumu apr\u016bpi, inovat\u012bvus materi\u0101lus un du\u0101la lietojuma funkcionalit\u0101ti<\/b><\/span><\/span><\/span><\/span>.<\/span><\/span><\/span><\/span><\/p>\n

Projekts veicina jaunu tehnolo\u0123iju un produktu izstr\u0101di, stiprinot Latvijas uz\u0146\u0113mumu p\u0113tniec\u012bbas un inov\u0101ciju kapacit\u0101ti un radot potenci\u0101lu risin\u0101jumu gan Latvijas, gan starptautiskajam tirgum.<\/span><\/span><\/span><\/span><\/p>\n

[\/vc_column_text][vc_single_image image=”3768″ img_size=”full” alignment=”center”][vc_column_text]2024.gada 22.apr\u012bl\u012b biedr\u012bba \u201cLatvijas \u0136\u012bmijas un farm\u0101cijas uz\u0146\u0113m\u0113ju asoci\u0101cija\u201d (turpm\u0101k – biedr\u012bba) un Centr\u0101l\u0101 finan\u0161u un l\u012bgumu a\u0123ent\u016bra parakst\u012bja L\u012bgumu par Eiropas Savien\u012bbas Atvese\u013co\u0161anas fonda projekta \u201cLatvijas Dz\u012bv\u012bbas zin\u0101t\u0146u nozares att\u012bst\u012bbas sadarb\u012bbas t\u012bkla p\u0113tniec\u012bbas un internacionaliz\u0101cijas veicin\u0101\u0161ana\u201d ievie\u0161anu, Projekta nr. Nr. 5.1.1.2.i.0\/3\/24\/A\/CFLA\/003 (turpm\u0101k \u2013 Projekts).<\/p>\n

Projekta \u012bsteno\u0161ana notiek sadarb\u012bbas t\u012bkla veid\u0101. Sadarb\u012bbas t\u012bklu veido vair\u0101k k\u0101 30 uz\u0146\u0113mumi, taj\u0101 skait\u0101 SIA Larif\u0101ns,vismaz viena p\u0113tniecisk\u0101 organiz\u0101cija un biedr\u012bba.<\/p>\n

Projekts tiek \u012bstenots sekojo\u0161\u0101s RIS3 jom\u0101s:<\/p>\n

– Biomedic\u012bna, medic\u012bnas tehnolo\u0123ijas, biofarm\u0101cija un biotehnolo\u0123ijas;<\/p>\n

– Viedie materi\u0101li, tehnolo\u0123ijas un in\u017eeniersist\u0113mas;<\/p>\n

– Inform\u0101cijas un komunik\u0101ciju tehnolo\u0123ijas.<\/p>\n

Projekta ietvaros pl\u0101not\u0101s aktivit\u0101tes ir v\u0113rstas uz jomas presti\u017ea cel\u0161anu un atbilsto\u0161as motiv\u0101cijas sist\u0113mas izveidi, sadarb\u012bbas t\u012bkla izveidi un darb\u012bbu, starptautisk\u0101s sadarb\u012bbas un eksporta apjoma pieauguma veicin\u0101\u0161anu.<\/p>\n

Projekts tie\u0161i veicin\u0101s sadarb\u012bbas t\u012bkla dal\u012bbnieku pieeju starptautiskajiem tirgiem, stiprin\u0101s nozares starptautisko konkur\u0113tsp\u0113ju, ka ar\u012b veicin\u0101s nozares popularit\u0101ti jaunatnes vid\u016b.<\/p>\n

Projekta aktivit\u0101tes ir v\u0113rstas uz sadarb\u012bbas t\u012bkla dal\u012bbnieku internacionaliz\u0101ciju un priv\u0101to p\u0113tniec\u012bbas un att\u012bst\u012bbas invest\u012bciju apjoma palielin\u0101\u0161anu.<\/p>\n

Projekta ilgums: 16.01.2024. \u2013 30.06.2026.<\/p>\n

Projekta kop\u0113jais bud\u017eets: 514\u00a0552 EUR<\/p>\n

ES Atvese\u013co\u0161an\u0101s fonda l\u012bdzfinans\u0113jums 85%: 437\u00a0369EUR;<\/p>\n

Priv\u0101tais l\u012bdzfinans\u0113jums: 77\u00a0183EUR.<\/p>\n

SIA \u201eLARIF\u0100NS\u201d <\/strong>06.05.2016. nosl\u0113dza ar LIAA l\u012bgumu Nr.SKV-L-2016\/227<\/strong> par atbalsta sa\u0146em\u0161anu projekta “Starptautisk\u0101s konkur\u0113tsp\u0113jas veicin\u0101\u0161ana” (projekta idintifik\u0101cijas numurs 3.2.1.2\/16\/I\/001), ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds. <\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 30.11.20215. nosl\u0113dza ar LIAA l\u012bgumu Nr.L.\u0100TA\/2.3.1.1.1\/15\/79\/137<\/strong> par atbalsta sa\u0146em\u0161anu projekta \u201eViz\u012bte kontaktbir\u017e\u0101 “BROKERAGE Event Horizon 2020” Ostrov\u0101, \u010cehij\u0101 2015. gada j\u016bnij\u0101 un izst\u0101d\u0113 CPhI Worldwide Madrid\u0113, Sp\u0101nij\u0101 2015. gada oktobr\u012b\u201d ietavros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 29.05.2015. nosl\u0113dza ar LIAA l\u012bgumu Nr.L-\u0100TA-15-2883<\/strong> par atbalsta sa\u0146em\u0161anu projekta \u201eViz\u012bte Tbilisi, Gruzij\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 02.04.2015. nosl\u0113dza ar LIAA l\u012bgumu Nr.L-\u0100TA-15-2703<\/strong> par atbalsta sa\u0146em\u0161anu projekta \u201eViz\u012bte Tbilisi un Batumi, Gruzij\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 26.09.2014. nosl\u0113dza ar LIAA l\u012bgumu Nr.L-\u0100TA-14-2370<\/strong> par atbalsta sa\u0146em\u0161anu projekta \u201eViz\u012bte Tad\u017eikist\u0101n\u0101 un Mongolij\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 09.07.2014. nosl\u0113dza ar LIAA l\u012bgumu Nr.L-\u0100TA-14-2236<\/strong>\u00a0 par atbalsta sa\u0146em\u0161anu projekta \u201eViz\u012bte Uzbekist\u0101n\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 18.07.2013. nosl\u0113dza ar LIAA l\u012bgumu Nr.L-\u0100TA-13-1578 <\/strong>par atbalsta sa\u0146em\u0161anu projekta\u00a0\u201eViz\u012bte Turkmenist\u0101n\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

SIA \u201eLARIF\u0100NS\u201d<\/strong> 09.07.2013. nosl\u0113dza ar LIAA l\u012bgumu Nr.L-\u0100TA-13-1556<\/strong> par atbalsta sa\u0146em\u0161anu projekta \u201eTirdzniec\u012bbas misija Moldov\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n

\n

2010. gada 1. oktobr\u012b BMC tika uzs\u0101kta ERAF 2.1.1.1. aktivit\u0101tes projekta\u00a0\u201ePrognostiska im\u016bnterapijas lietder\u012bguma un efektivit\u0101tes test\u0113\u0161ana: metodes izveide personaliz\u0113tai im\u016bnterapeitisko prepar\u0101tu pielieto\u0161anai onkolo\u0123ij\u0101\u201d\u00a0<\/strong>\u012bsteno\u0161ana.<\/span><\/p>\n

Projekts tiek \u012bstenots ERAF 2.1.1.1. aktivit\u0101tes \u201eAtbalsts zin\u0101tnei un p\u0113tniec\u012bbai\u201d ietvaros<\/span>
\nProjekta vieno\u0161an\u0101s Nr. 2010\/0233\/2DP\/2.1.1.1.0\/10\/APIA\/VIAA\/076<\/span>
\nProjekta izpildes termi\u0146\u0161: 36 m\u0113ne\u0161i (01.10.2010.-30.09.2013.)<\/span>
\nProjekta kop\u0113jais finans\u0113jums: 294938 LVL<\/span>
\nProjekta zin\u0101tnisk\u0101 vad\u012bt\u0101ja: Dr. Dace Pjanova<\/span><\/p>\n

Projekta\u00a0visp\u0101r\u012bgais m\u0113r\u0137is<\/strong>\u00a0ir uzlabota onkolo\u0123isko pacientu im\u016bnterapijas efektivit\u0101te.<\/span><\/p>\n<\/div>\n

Projekta\u00a0specifiskais m\u0113r\u0137is<\/strong>\u00a0ir personaliz\u0113tas prognostiskas\u00a0in vitro<\/em>\u00a0test\u0113\u0161anas metodes izveide im\u016bnterapetisko prepar\u0101tu lieto\u0161anas lietder\u012bguma paredz\u0113\u0161anai pirms terapijas uzs\u0101k\u0161anas.<\/span><\/div>\n
<\/div>\n
Lai nodro\u0161in\u0101tu m\u0113r\u0137u sasnieg\u0161anu, projekta ietvaros pl\u0101nots \u012bstenot \u0161\u0101das\u00a0aktivit\u0101tes<\/strong>:<\/span><\/div>\n
<\/div>\n
1. P\u0113tniec\u012bba (r\u016bpnieciskais p\u0113t\u012bjums):<\/span><\/div>\n
1.1. prepar\u0101tu ierosin\u0101to limfoc\u012btu sub-popul\u0101ciju noteik\u0161ana,<\/span><\/div>\n
<\/div>\n
1.2. prepar\u0101tu ierosin\u0101to limfoc\u012btu aktivit\u0101tes noteik\u0161ana,<\/span><\/div>\n
<\/div>\n
1.3. prepar\u0101tu ierosin\u0101to limfoc\u012btu ekspansijas noteik\u0161ana atsevi\u0161\u0137\u0101s sub-popul\u0101cij\u0101s un to<\/span><\/div>\n
aktivit\u0101tes noteik\u0161ana da\u017e\u0101d\u0101s onkolo\u0123isko pacientu grup\u0101s,<\/span><\/div>\n
<\/div>\n
1.4. Personaliz\u0113tas prognostiskas im\u016bnterapeitisko prepar\u0101tu efekta in vitro test\u0113\u0161anas<\/span><\/div>\n
metodikas izstr\u0101de.<\/span><\/div>\n
<\/div>\n
\n

2. P\u0113tniec\u012bbas rezult\u0101tu publiskas pieejam\u012bbas nodro\u0161in\u0101\u0161ana<\/span><\/p>\n

Projekta rezult\u0101t\u0101<\/strong>\u00a0tiks izstr\u0101d\u0101ta personaliz\u0113ta prognostiska im\u016bnterapeitisko prepar\u0101tu lieto\u0161anas lietder\u012bguma un efektivit\u0101tes in vitro test\u0113\u0161anas metodika ar pielietojumu kl\u012bnik\u0101 onkolo\u0123isko pacientu im\u016bnterapijas prognoz\u0113jam\u012bbas paaugstin\u0101\u0161anai un im\u016bnterapijas efektivit\u0101tes palielin\u0101\u0161anai, piemekl\u0113jot katram pacientam piem\u0113rot\u0101ko prepar\u0101tu un devu. Projekta rezult\u0101t\u0101 tiks izstr\u0101d\u0101ts metodes detaliz\u0113ts aprakts.<\/span><\/p>\n

\n<\/div>\n

Vair\u0101k inform\u0101cijas var apskat\u012bt \u0161eit..<\/a><\/span>[\/vc_column_text][\/vc_column][vc_column][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row overflow=”default” css=”.vc_custom_1643308766592{border-top-width: 60px !important;padding-bottom: 60px !important;}”][vc_column][vc_column_text] Jaunas inovat\u012bvas du\u0101la lietojuma medic\u012bnas ier\u012bces izstr\u0101de SIA\u00a0\u201cLarif\u0101ns\u201d\u00a0piedal\u0101s Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonda (ERAF) atbalst\u012bt\u0101 projekt\u0101\u00a0\u201cJaunas inovat\u012bvas du\u0101la lietojuma medic\u012bnas ier\u012bces izstr\u0101de\u201d, projekta Nr.\u00a01.2.1.1\/3\/26\/A\/095. Projekta \u012bsteno\u0161ana pl\u0101nota laika period\u0101 no\u00a02026. gada septembra l\u012bdz 2028. gada augustam. Projekta kop\u0113jais bud\u017eets:\u00a01…<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"disable_featured_image":false},"aioseo_notices":[],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/pages\/1874"}],"collection":[{"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/comments?post=1874"}],"version-history":[{"count":19,"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/pages\/1874\/revisions"}],"predecessor-version":[{"id":3874,"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/pages\/1874\/revisions\/3874"}],"wp:attachment":[{"href":"https:\/\/larifan.eu\/ru\/wp-json\/wp\/v2\/media?parent=1874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}